Erste Asset Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Erste Asset Management’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-120,000	Closed	-$1.24M	–	548
2024 Q3	$1.24M	Hold	120,000	–	–	0.01%	368
2024 Q2	$1.56M	Hold	120,000	–	–	0.02%	334
2024 Q1	$2.1M	Hold	120,000	–	–	0.03%	298
2023 Q4	$1.13M	Buy	120,000 +25,500	+27%	+$238K	0.02%	365
2023 Q3	$1.06M	Hold	94,500	–	–	0.02%	341
2023 Q2	$2.01M	Hold	94,500	–	–	0.04%	288
2023 Q1	$3.79M	Hold	94,500	–	–	0.07%	241
2022 Q4	$4.4M	Buy	94,500 +20,000	+27%	+$912K	0.09%	218
2022 Q3	$3.88M	Hold	74,500	–	–	0.09%	228
2022 Q2	$3.51M	Hold	74,500	–	–	0.08%	242
2022 Q1	$5.25M	Buy	+74,500	New	+$4.85M	0.1%	212
2020 Q4	–	Sell	-6,200	Closed	-$278K	–	497
2020 Q3	$278K	Hold	6,200	–	–	0.01%	378
2020 Q2	$304K	Hold	6,200	–	–	0.01%	364
2020 Q1	$314K	Hold	6,200	–	–	0.02%	331
2019 Q4	$388K	Hold	6,200	–	–	0.02%	338
2019 Q3	$374K	Hold	6,200	–	–	0.02%	339
2019 Q2	$520K	Hold	6,200	–	–	0.03%	315
2019 Q1	$591K	Buy	+6,200	New	+$556K	0.03%	298

Other funds holding ENTA

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Erste Asset Management's ENTA Position: Q4 2024 in Review

Erste Asset Management sold out of Enanta Pharmaceuticals (ENTA) in Q4 2024, closing a stake of 120,000 shares — an estimated $1.24M sold.

Erste Asset Management first reported a position in ENTA in Q1 2019 and held it in 18 quarters. The position peaked at $5.25M in Q1 2022. 107 funds tracked by Wall St. Rank hold ENTA as of Q4 2024.

Erste Asset Management reported no remaining Enanta Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Erste Asset Management sold 120,000 Enanta Pharmaceuticals shares in Q4 2024, an estimated $1.24M.
Erste Asset Management first reported a position in Enanta Pharmaceuticals in Q1 2019 and held it in 18 quarters.
Erste Asset Management's Enanta Pharmaceuticals position peaked at $5.25M in Q1 2022.
107 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2024.

Based on Erste Asset Management's 13F filing for Q4 2024, filed 10 Feb 2025.